Logo image of OKYO

OKYO PHARMA LTD (OKYO) Stock Fundamental Analysis

USA - NASDAQ:OKYO - GG00BMFG5F62 - Common Stock

2.39 USD
+0.15 (+6.7%)
Last: 10/24/2025, 8:00:02 PM
2.43 USD
+0.04 (+1.67%)
After Hours: 10/24/2025, 8:00:02 PM
Fundamental Rating

0

OKYO gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. OKYO may be in some trouble as it scores bad on both profitability and health. OKYO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OKYO had negative earnings in the past year.
OKYO had a negative operating cash flow in the past year.
In the past 5 years OKYO always reported negative net income.
In the past 5 years OKYO always reported negative operating cash flow.
OKYO Yearly Net Income VS EBIT VS OCF VS FCFOKYO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M

1.2 Ratios

OKYO has a worse Return On Assets (-127.98%) than 82.21% of its industry peers.
Industry RankSector Rank
ROA -127.98%
ROE N/A
ROIC N/A
ROA(3y)-491.55%
ROA(5y)-329.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OKYO Yearly ROA, ROE, ROICOKYO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OKYO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OKYO Yearly Profit, Operating, Gross MarginsOKYO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, OKYO has more shares outstanding
Compared to 5 years ago, OKYO has more shares outstanding
There is no outstanding debt for OKYO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
OKYO Yearly Shares OutstandingOKYO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
OKYO Yearly Total Debt VS Total AssetsOKYO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M

2.2 Solvency

Based on the Altman-Z score of -59.24, we must say that OKYO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of OKYO (-59.24) is worse than 94.38% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -59.24
ROIC/WACCN/A
WACCN/A
OKYO Yearly LT Debt VS Equity VS FCFOKYO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 2M -2M -4M -6M -8M

2.3 Liquidity

A Current Ratio of 0.40 indicates that OKYO may have some problems paying its short term obligations.
OKYO has a worse Current ratio (0.40) than 93.82% of its industry peers.
OKYO has a Quick Ratio of 0.40. This is a bad value and indicates that OKYO is not financially healthy enough and could expect problems in meeting its short term obligations.
OKYO has a Quick ratio of 0.40. This is amonst the worse of the industry: OKYO underperforms 93.45% of its industry peers.
Industry RankSector Rank
Current Ratio 0.4
Quick Ratio 0.4
OKYO Yearly Current Assets VS Current LiabilitesOKYO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 79.21% over the past year.
EPS 1Y (TTM)79.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.76%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OKYO Yearly EPS VS EstimatesOKYO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -0.1 -0.2 -0.3 -0.4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OKYO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OKYO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OKYO Price Earnings VS Forward Price EarningsOKYO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OKYO Per share dataOKYO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

OKYO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OKYO PHARMA LTD

NASDAQ:OKYO (10/24/2025, 8:00:02 PM)

After market: 2.43 +0.04 (+1.67%)

2.39

+0.15 (+6.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)12-22 2025-12-22
Inst Owners7.37%
Inst Owner Change0%
Ins Owners33.31%
Ins Owner Change0%
Market Cap52.03M
Revenue(TTM)N/A
Net Income(TTM)-4706300
Analysts82.5
Price Target10.2 (326.78%)
Short Float %0.12%
Short Ratio0.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)42.86%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-11.76%
EPS NY rev (3m)-11.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS0
BVpS-0.34
TBVpS-0.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -127.98%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-491.55%
ROA(5y)-329.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.4
Quick Ratio 0.4
Altman-Z -59.24
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)67.14%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.03%
EPS Next Y-11.76%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y80.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.92%
OCF growth 3YN/A
OCF growth 5YN/A

OKYO PHARMA LTD / OKYO FAQ

What is the ChartMill fundamental rating of OKYO PHARMA LTD (OKYO) stock?

ChartMill assigns a fundamental rating of 0 / 10 to OKYO.


Can you provide the valuation status for OKYO PHARMA LTD?

ChartMill assigns a valuation rating of 0 / 10 to OKYO PHARMA LTD (OKYO). This can be considered as Overvalued.


Can you provide the profitability details for OKYO PHARMA LTD?

OKYO PHARMA LTD (OKYO) has a profitability rating of 0 / 10.


Can you provide the financial health for OKYO stock?

The financial health rating of OKYO PHARMA LTD (OKYO) is 0 / 10.